Oligonucleotide API Market: Opportunities & Forecast 2024-2034

Oligonucleotide API Market Outlook from 2024 to 2034

Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 5.60% from 2024 to 2034. As such, the global oligonucleotide API market is projected to increase from a valuation of US$ 2.81 billion in 2024 to US$ 4.84 billion by the end of 2034.

Attributes	Key Statistics
Expected Base Year Value (2024)	US$ 2.81 billion
Anticipated Forecast Value (2034)	US$ 4.84 billion
Estimated Growth (2024 to 2034)	5.60% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Market Drivers

The increasing number of oligonucleotide-active pharmaceutical ingredients in medication pipelines around the world is a major driver of market growth. Pharma businesses have benefited from the ongoing trend toward harmonization of oligonucleotide development and marketing over the last 10-15 years. Several other reasons are also leading to the growth of the oligonucleotide API market:

Expansion of synthetic biology applications due to the demand for custom oligonucleotide synthesis, enabling precise control over gene expression and metabolic pathway
Emergence of CRISPR-Cas gene editing technology fuelling demand for oligonucleotides as tools for genetic manipulation, facilitating targeted genome modifications with high efficiency
Rising adoption of RNA-based therapeutics, such as mRNA vaccines and RNA interference therapies, leveraging oligonucleotides for precise modulation of gene expression and protein synthesis
Growing use of oligonucleotides in molecular diagnostics for detecting genetic mutations and infectious diseases, offering rapid and accurate detection with high specificity
Increasing research focus on antisense oligonucleotides for treating neurological disorders and cancer, exploiting their ability to target disease-causing genes and protein
Advancements in oligonucleotide synthesis techniques, enhancing scalability and cost-effectiveness, enabling the production of high-quality oligonucleotides at larger scales
Demand for oligonucleotide APIs in agricultural biotechnology for crop improvement and pest management, harnessing their potential for enhancing plant traits and controlling agricultural pests
Expansion of contract manufacturing organizations (CMOs) offering oligonucleotide synthesis services, and providing outsourcing solutions for pharmaceutical companies and research institutions
Collaborations between academia, pharmaceutical companies, and government institutions to advance oligonucleotide-based therapies, fostering interdisciplinary research and development efforts.
Heightened interest in oligonucleotide-based therapies targeting rare diseases and oncology indications, addressing unmet medical needs and offering potential breakthrough treatments.

Trends in the Global Oligonucleotide API Market

mRNA vaccines, including those for COVID-19, have brought attention to the potential of oligonucleotide APIs in vaccine development, leading to increased investment and research in this area.
ASOs are gaining interest as a treatment option for various genetic disorders, including rare diseases and neurodegenerative conditions. This is also driving the demand for oligonucleotide APIs tailored for ASO therapeutics.
Innovations in delivery systems, such as lipid nanoparticles and conjugates, are improving the efficacy and safety of oligonucleotide drugs. This is contributing to market growth as these technologies become essential parts of oligonucleotide API development.
The increasing complexity and specificity required in oligonucleotide-based therapies are also driving the demand for customized synthesis services from CDMOs.
Oligonucleotide APIs are also playing a crucial role in the advancement of precision medicine, enabling targeted therapies based on individual genetic profiles. As personalized treatment approaches become more widespread, the demand for oligonucleotide APIs is likely to increase.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Complex and Time-consuming Processes to Slow down the Market Growth for Oligonucleotide APIs

Pharmaceutical companies may be hesitant to invest in areas with smaller patient populations due to the high research and development costs associated with oligonucleotide therapies.
Oligonucleotide synthesis and purification processes can be complex and time-consuming, leading to challenges in scaling up production and limiting supply, which also impedes market growth.
Regulatory hurdles related to safety, efficacy, and manufacturing standards also lead to delays in approvals and market entry, particularly for complex oligonucleotide APIs.
Despite the increasing demand, commercialization of oligonucleotide-based therapies is still relatively new compared to traditional drugs, and companies may lack experience in marketing and distribution, which substantially slows down market growth.
Oligonucleotide-based therapies face competition from alternative treatment modalities, such as small molecules, biologics, and gene therapies, which significantly limits market penetration.

Comparative View of Adjacent Industries

Our analysts have analyzed the Oligonucleotide API market, and two other related markets-the small molecule API market and the antibiotics active pharmaceutical ingredient (API) market-that have the potential to give rigorous competition in the coming decade.

This analysis helps us understand the growth rate and growth factors shaping the future of these markets. Based on these numbers, it can be confidently projected that the market for oligonucleotide APIs is very likely to have more opportunities in the future.

Oligonucleotide API Market:

Attributes	Oligonucleotide API Market
CAGR (2024 to 2034)	5.60%
Market Value (2024)	US$ 28.10 billion
Growth Factor	Rising adoption of RNA-based therapeutics, such as mRNA vaccines and RNA interference therapies Collaborations between academia, pharmaceutical companies, and government institutions to advance oligonucleotide-based therapies.

Small Molecule API Market:

Attributes	Small Molecule API Market
CAGR (2023 to 2033)	4.10%
Market Value (2023)	US$ 116 billion
Growth Factor	Increasingly advanced materials science and the emergence of new applications are driving the small molecule API market. The upcoming patent expirations of the most popular pharmaceuticals are driving the growth of the small molecule API market.

Antibiotics Active Pharmaceutical Ingredient (API) Market:

Attributes	Antibiotics Active Pharmaceutical Ingredient (API) Market
CAGR (2023 to 2033)	3.30%
Market Value (2023)	US$ 8653.0 million
Growth Factor	The approval of licenses for the new drugs is expected to drive growth in the market since only a few are based on novel chemical entities. Generic antibiotics are significantly more affordable compared to proprietary compounds. This cost differential has led to an increase in the launch of generic versions, which is expected to have a positive impact on the global market.

Category-wise Insights

ASOs to Gain Popularity in the Global Healthcare Sector

The antisense oligonucleotide APIs category is projected to hold the largest share of the market in the year 2024. This segment holds 78% of the global oligonucleotide API market.

The demand for ASOs in the healthcare sector is experiencing a tremendous surge as they offer precise targeting of specific RNA sequences implicated in disease pathways. This allows for highly targeted therapeutic interventions with potentially fewer off-target effects.
ASOs have demonstrated therapeutic potential across a wide range of diseases, including rare genetic disorders, neurodegenerative diseases, and various types of cancer. This is also one of the main reasons for their popularity in the healthcare sector.

Attributes	Details
API	Antisense Oligonucleotides API
Market Share	78%

Oligonucleotide APIs to find their place in Pharmaceutical and Biopharmaceutical Companies

The oligonucleotide API market is also categorized by end-users into CMOs, pharmaceutical and biopharmaceutical companies, and contract development & manufacturing organizations. The pharmaceutical and biopharmaceutical companies segment dominates the market with a share of 49% in 2024.

Oligonucleotide APIs are being increasingly preferred by pharmaceutical and biopharmaceutical companies as they enable the development of targeted therapies that can specifically modulate gene expression or protein function.
The promising clinical prospects and market potential of oligonucleotide-based therapies have attracted significant investor interest, providing funding and support for pharmaceutical and biopharmaceutical companies. This has also increased their acceptance in the international marketplace.

Attributes	Details
End User	Pharmaceutical and Biopharmaceutical Companies
Market Share	49%

Country-wise Insights

This section offers a comprehensive analysis of the oligonucleotide APIs market across various countries, including India, Thailand, Malaysia, Indonesia, and France. The table presents the Compound Annual Growth Rate (CAGR) for each country, depicting the estimated market growth in these regions until 2034.

Countries	CAGR
India	7.80%
Thailand	6.20%
Malaysia	5.90%
Indonesia	5.40%
France	4.20%

Thriving Pharma Manufacturing Capability to Drive Market Growth in India

India is expected to exhibit significant market growth over the forecast period. The Indian market for oligonucleotide APIs is anticipated to grow at a CAGR of 7.80%.

India has a thriving pharmaceutical manufacturing industry that specializes in producing oligonucleotide APIs. The country's well-established infrastructure and highly skilled workforce make it a desirable destination for oligonucleotide API production.
Indian manufacturers also offer cost-competitive solutions due to lower production costs, making oligonucleotide APIs more affordable for global markets.

Government Support Boosts Thai Oligonucleotide API Market

Thailand is also one of the lucrative markets in the oligonucleotide APIs industry. The Thai market for oligonucleotide APIs is anticipated to grow at a CAGR of 6.20%.

The Thai government has implemented innovative policies to promote the biotechnology and pharmaceutical industries, providing incentives for research, development, and manufacturing of oligonucleotide APIs.
Thailand's strategic location in Southeast Asia also provides access to regional markets and supply chains, enhancing its competitiveness in the oligonucleotide APIs market.

Significant Investments by Public and Private Entities to Bolster Market Growth in Malaysia

Malaysia also is a promising market in the global oligonucleotide APIs industry. Over the next ten years, the Malaysian demand for oligonucleotide APIs is projected to rise at a 5.90% CAGR.

Malaysia has made significant investments in biotechnology infrastructure and research capabilities. This has positioned itself as a hub for biopharmaceutical development of oligonucleotide APIs.
Malaysia also boasts a skilled and educated workforce in the biotechnology and pharmaceutical sectors, supporting the development and manufacturing of complex oligonucleotides.

Collaborative Partnerships to Fuel Market Growth in Indonesia

Indonesia is also one of the countries that is filled with potential in this market. The Indonesian oligonucleotide API market is anticipated to retain its dominance by progressing at a growth rate of 5.40% till 2034.

Indonesia's large and growing population presents a significant market opportunity for oligonucleotide APIs. This has increased the adoption of oligonucleotide APIs in the country.
Collaborations between Indonesian companies and international partners are also enhancing technology transfer and knowledge exchange in oligonucleotide API production.

French Oligonucleotide API Market to Expand Due to Well-established Regulatory Framework

France also exhibits a promising future in the global oligonucleotide APIs market. The oligonucleotide APIs market in France is anticipated to retain its dominance by progressing at a growth rate of 4.20% till 2034.

The French government also provides funding and support for biopharmaceutical research and innovation initiatives, such as the French National Research Agency (ANR). This has also driven advancements in oligonucleotide APIs and strengthened France's position in the global market.
The country also has a well-established regulatory framework for the biopharmaceutical industry, providing a favorable environment for oligonucleotide API development and commercialization.

Competitive Landscape

The global oligonucleotide active pharmaceutical ingredient (API) market is still in its early stages and is dominated by a few key players. These include Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, and Alnylam Pharmaceuticals, Inc.

However, the market is expected to grow with strategic partnerships and the introduction of new products by industry leaders. To stay competitive in this market, companies need to have a strong creative and innovative capacity.

Recent Developments

In September 2023, ST Pharm broke ground on its second oligonucleotide manufacturing plant in Ansan, Gyeonggi Province. The $830.9 million investment aimed to establish the world's largest oligonucleotide API manufacturer, with projected production capabilities of 14 mol.
In May 2022, Bachem and Eli Lilly & Co. initiated a strategic collaboration to develop and manufacture oligonucleotide-based active pharmaceutical ingredients. Bachem provided engineering infrastructure and personnel at its Switzerland facilities, with Lilly committing to placing manufacturing projects worth around CHF 100 million over seven years.
In November 2021, Korea's ST Pharm announced a $126 million investment to construct its second oligonucleotide manufacturing plant, doubling its capacity to 14 moles per year by 2025, positioning it as the world's largest oligonucleotide CDMO.

Key Companies in the Market

Jazz Pharmaceuticals, Inc.
Sarepta Therapeutics
Biogen
Dynavax Technologies
Akcea Therapeutics.
Alnylam Pharmaceuticals, Inc.

Key Coverage in the Oligonucleotide API Industry Report

General Insights on the Oligonucleotide GMP Manufacturing
Antisense Oligonucleotide API Market
Oligonucleotide API Market in India
Oligonucleotide API Manufacturers
Assuring Quality of Oligonucleotide APIs and DPs

Oligonucleotide API Market Segmentation

By API:

Antisense Oligonucleotides APIs
Short Interfering RNA (siRNA) APIs
Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
MiRNA APIs
Aptamers APIs
CpG Oligonucleotides APIs
Others (ON Conjugates (NP), ShRNA, etc.)

By Marketing Status:

Marketed
Clinical Trials (Clinical Phases)

By End User:

Contract Manufacturing Organizations (CMOs)
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Development & Manufacturing Organizations (CDMOs)

By Region:

North America
Latin America
Asia Pacific
Middle East and Africa (MEA)
Europe

Frequently Asked Questions

How much is the Oligonucleotide API Market Currently Worth?

The oligonucleotide API market is expected to be worth US$ 2810.3 million by 2024.

What is the Sales Forecast for Oligonucleotide API through 2034?

The market for oligonucleotide API is expected to reach US$ 4846.1 million by 2034.

At what rate is the Oligonucleotide API Market growing?

The oligonucleotide API market is growing at a CAGR of 5.60% from 2024 to 2034.

Who are the key Companies in the Oligonucleotide API Market?

Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, and Alnylam Pharmaceuticals, Inc, etc. are some of the major players in the market for oligonucleotide API.

What was the overall Value of the Oligonucleotide API Market in 2023?

The valuation for the oligonucleotide API market in 2023 was US$ 2712.60 million.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Product Life Cycle Analysis

3.5. Supply Chain Analysis

3.5.1. Supply Side Participants and their Roles

3.5.1.1. Manufacturer

3.5.1.2. Mid-Level Participants (Traders)

3.5.1.3. Distributors

3.5.2. Value Added and Value Created at Node in the Supply Chain

3.5.3. List of Raw Material Suppliers

3.5.4. List of Existing and Potential Buyer’s

3.6. Investment Feasibility Matrix

3.7. Value Chain Analysis

3.7.1. Profit Margin Analysis

3.7.2. Distributors

3.8. PESTLE and Porter’s Analysis

3.9. Regulatory Landscape

3.9.1. By Key Regions

3.9.2. By Key Countries

3.10. Regional Parent Market Outlook

3.11. Production and Consumption Statistics

3.12. Import and Export Statistics

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

4.1. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis, 2019 to 2023

4.2. Current and Future Market Size Value (US$ Million) & Volume (Tons) Projections, 2024 to 2034

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By API

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By API, 2019 to 2023

5.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By API, 2024 to 2034

5.3.1. Antisense Oligonucleotides APIs

5.3.2. Short Interfering RNA (siRNA) APIs

5.3.3. Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs

5.3.4. MiRNA APIs

5.3.5. Aptamers APIs

5.3.6. CpG Oligonucleotides APIs

5.3.7. Others (ON Conjugates (NP), ShRNA, etc.)

5.4. Y-o-Y Growth Trend Analysis By API, 2019 to 2023

5.5. Absolute $ Opportunity Analysis By API, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Marketing Status

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Marketing Status, 2019 to 2023

6.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Marketing Status, 2024 to 2034

6.3.1. Marketed

6.3.2. Clinical Trials (Clinical Phases)

6.4. Y-o-Y Growth Trend Analysis By Marketing Status, 2019 to 2023

6.5. Absolute $ Opportunity Analysis By Marketing Status, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By End User, 2019 to 2023

7.3. Current and Future Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By End User, 2024 to 2034

7.3.1. Contract Manufacturing Organizations (CMOs)

7.3.2. Pharmaceutical Companies

7.3.3. Biopharmaceutical Companies

7.3.4. Contract Development & Manufacturing Organizations (CDMOs)

7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023

7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

8.1. Introduction

8.2. Historical Market Size Value (US$ Million) & Volume (Tons) Analysis By Region, 2019 to 2023

8.3. Current Market Size Value (US$ Million) & Volume (Tons) Analysis and Forecast By Region, 2024 to 2034

8.3.1. North America

8.3.2. Latin America

8.3.3. Western Europe

8.3.4. Eastern Europe

8.3.5. South Asia and Pacific

8.3.6. East Asia

8.3.7. Middle East and Africa

8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

9.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

9.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

9.2.1. By Country

9.2.1.1. USA

9.2.1.2. Canada

9.2.2. By API

9.2.3. By Marketing Status

9.2.4. By End User

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By API

9.3.3. By Marketing Status

9.3.4. By End User

9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

10.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

10.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

10.2.1. By Country

10.2.1.1. Brazil

10.2.1.2. Mexico

10.2.1.3. Rest of Latin America

10.2.2. By API

10.2.3. By Marketing Status

10.2.4. By End User

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By API

10.3.3. By Marketing Status

10.3.4. By End User

10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

11.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

11.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

11.2.1. By Country

11.2.1.1. Germany

11.2.1.2. UK

11.2.1.3. France

11.2.1.4. Spain

11.2.1.5. Italy

11.2.1.6. Rest of Western Europe

11.2.2. By API

11.2.3. By Marketing Status

11.2.4. By End User

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By API

11.3.3. By Marketing Status

11.3.4. By End User

11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

12.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

12.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

12.2.1. By Country

12.2.1.1. Poland

12.2.1.2. Russia

12.2.1.3. Czech Republic

12.2.1.4. Romania

12.2.1.5. Rest of Eastern Europe

12.2.2. By API

12.2.3. By Marketing Status

12.2.4. By End User

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By API

12.3.3. By Marketing Status

12.3.4. By End User

12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

13.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

13.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

13.2.1. By Country

13.2.1.1. India

13.2.1.2. Bangladesh

13.2.1.3. Australia

13.2.1.4. New Zealand

13.2.1.5. Rest of South Asia and Pacific

13.2.2. By API

13.2.3. By Marketing Status

13.2.4. By End User

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By API

13.3.3. By Marketing Status

13.3.4. By End User

13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

14.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

14.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

14.2.1. By Country

14.2.1.1. China

14.2.1.2. Japan

14.2.1.3. South Korea

14.2.2. By API

14.2.3. By Marketing Status

14.2.4. By End User

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By API

14.3.3. By Marketing Status

14.3.4. By End User

14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

15.1. Historical Market Size Value (US$ Million) & Volume (Tons) Trend Analysis By Market Taxonomy, 2019 to 2023

15.2. Market Size Value (US$ Million) & Volume (Tons) Forecast By Market Taxonomy, 2024 to 2034

15.2.1. By Country

15.2.1.1. GCC Countries

15.2.1.2. South Africa

15.2.1.3. Israel

15.2.1.4. Rest of MEA

15.2.2. By API

15.2.3. By Marketing Status

15.2.4. By End User

15.3. Market Attractiveness Analysis

15.3.1. By Country

15.3.2. By API

15.3.3. By Marketing Status

15.3.4. By End User

15.4. Key Takeaways

16. Key Countries Market Analysis

16.1. USA

16.1.1. Pricing Analysis

16.1.2. Market Share Analysis, 2023

16.1.2.1. By API

16.1.2.2. By Marketing Status

16.1.2.3. By End User

16.2. Canada

16.2.1. Pricing Analysis

16.2.2. Market Share Analysis, 2023

16.2.2.1. By API

16.2.2.2. By Marketing Status

16.2.2.3. By End User

16.3. Brazil

16.3.1. Pricing Analysis

16.3.2. Market Share Analysis, 2023

16.3.2.1. By API

16.3.2.2. By Marketing Status

16.3.2.3. By End User

16.4. Mexico

16.4.1. Pricing Analysis

16.4.2. Market Share Analysis, 2023

16.4.2.1. By API

16.4.2.2. By Marketing Status

16.4.2.3. By End User

16.5. Germany

16.5.1. Pricing Analysis

16.5.2. Market Share Analysis, 2023

16.5.2.1. By API

16.5.2.2. By Marketing Status

16.5.2.3. By End User

16.6. UK

16.6.1. Pricing Analysis

16.6.2. Market Share Analysis, 2023

16.6.2.1. By API

16.6.2.2. By Marketing Status

16.6.2.3. By End User

16.7. France

16.7.1. Pricing Analysis

16.7.2. Market Share Analysis, 2023

16.7.2.1. By API

16.7.2.2. By Marketing Status

16.7.2.3. By End User

16.8. Spain

16.8.1. Pricing Analysis

16.8.2. Market Share Analysis, 2023

16.8.2.1. By API

16.8.2.2. By Marketing Status

16.8.2.3. By End User

16.9. Italy

16.9.1. Pricing Analysis

16.9.2. Market Share Analysis, 2023

16.9.2.1. By API

16.9.2.2. By Marketing Status

16.9.2.3. By End User

16.10. Poland

16.10.1. Pricing Analysis

16.10.2. Market Share Analysis, 2023

16.10.2.1. By API

16.10.2.2. By Marketing Status

16.10.2.3. By End User

16.11. Russia

16.11.1. Pricing Analysis

16.11.2. Market Share Analysis, 2023

16.11.2.1. By API

16.11.2.2. By Marketing Status

16.11.2.3. By End User

16.12. Czech Republic

16.12.1. Pricing Analysis

16.12.2. Market Share Analysis, 2023

16.12.2.1. By API

16.12.2.2. By Marketing Status

16.12.2.3. By End User

16.13. Romania

16.13.1. Pricing Analysis

16.13.2. Market Share Analysis, 2023

16.13.2.1. By API

16.13.2.2. By Marketing Status

16.13.2.3. By End User

16.14. India

16.14.1. Pricing Analysis

16.14.2. Market Share Analysis, 2023

16.14.2.1. By API

16.14.2.2. By Marketing Status

16.14.2.3. By End User

16.15. Bangladesh

16.15.1. Pricing Analysis

16.15.2. Market Share Analysis, 2023

16.15.2.1. By API

16.15.2.2. By Marketing Status

16.15.2.3. By End User

16.16. Australia

16.16.1. Pricing Analysis

16.16.2. Market Share Analysis, 2023

16.16.2.1. By API

16.16.2.2. By Marketing Status

16.16.2.3. By End User

16.17. New Zealand

16.17.1. Pricing Analysis

16.17.2. Market Share Analysis, 2023

16.17.2.1. By API

16.17.2.2. By Marketing Status

16.17.2.3. By End User

16.18. China

16.18.1. Pricing Analysis

16.18.2. Market Share Analysis, 2023

16.18.2.1. By API

16.18.2.2. By Marketing Status

16.18.2.3. By End User

16.19. Japan

16.19.1. Pricing Analysis

16.19.2. Market Share Analysis, 2023

16.19.2.1. By API

16.19.2.2. By Marketing Status

16.19.2.3. By End User

16.20. South Korea

16.20.1. Pricing Analysis

16.20.2. Market Share Analysis, 2023

16.20.2.1. By API

16.20.2.2. By Marketing Status

16.20.2.3. By End User

16.21. GCC Countries

16.21.1. Pricing Analysis

16.21.2. Market Share Analysis, 2023

16.21.2.1. By API

16.21.2.2. By Marketing Status

16.21.2.3. By End User

16.22. South Africa

16.22.1. Pricing Analysis

16.22.2. Market Share Analysis, 2023

16.22.2.1. By API

16.22.2.2. By Marketing Status

16.22.2.3. By End User

16.23. Israel

16.23.1. Pricing Analysis

16.23.2. Market Share Analysis, 2023

16.23.2.1. By API

16.23.2.2. By Marketing Status

16.23.2.3. By End User

17. Market Structure Analysis

17.1. Competition Dashboard

17.2. Competition Benchmarking

17.3. Market Share Analysis of Top Players

17.3.1. By Regional

17.3.2. By API

17.3.3. By Marketing Status

17.3.4. By End User

18. Competition Analysis

18.1. Competition Deep Dive

18.1.1. Jazz Pharmaceuticals, Inc.

18.1.1.1. Overview

18.1.1.2. Product Portfolio

18.1.1.3. Profitability by Market Segments

18.1.1.4. Sales Footprint

18.1.1.5. Strategy Overview

18.1.1.5.1. Marketing Strategy

18.1.1.5.2. Product Strategy

18.1.1.5.3. Channel Strategy

18.1.2. Sarepta Therapeutics

18.1.2.1. Overview

18.1.2.2. Product Portfolio

18.1.2.3. Profitability by Market Segments

18.1.2.4. Sales Footprint

18.1.2.5. Strategy Overview

18.1.2.5.1. Marketing Strategy

18.1.2.5.2. Product Strategy

18.1.2.5.3. Channel Strategy

18.1.3. Biogen

18.1.3.1. Overview

18.1.3.2. Product Portfolio

18.1.3.3. Profitability by Market Segments

18.1.3.4. Sales Footprint

18.1.3.5. Strategy Overview

18.1.3.5.1. Marketing Strategy

18.1.3.5.2. Product Strategy

18.1.3.5.3. Channel Strategy

18.1.4. Dynavax Technologies

18.1.4.1. Overview

18.1.4.2. Product Portfolio

18.1.4.3. Profitability by Market Segments

18.1.4.4. Sales Footprint

18.1.4.5. Strategy Overview

18.1.4.5.1. Marketing Strategy

18.1.4.5.2. Product Strategy

18.1.4.5.3. Channel Strategy

18.1.5. Akcea Therapeutics.

18.1.5.1. Overview

18.1.5.2. Product Portfolio

18.1.5.3. Profitability by Market Segments

18.1.5.4. Sales Footprint

18.1.5.5. Strategy Overview

18.1.5.5.1. Marketing Strategy

18.1.5.5.2. Product Strategy

18.1.5.5.3. Channel Strategy

18.1.6. Alnylam Pharmaceuticals, Inc.

18.1.6.1. Overview

18.1.6.2. Product Portfolio

18.1.6.3. Profitability by Market Segments

18.1.6.4. Sales Footprint

18.1.6.5. Strategy Overview

18.1.6.5.1. Marketing Strategy

18.1.6.5.2. Product Strategy

18.1.6.5.3. Channel Strategy

18.1.7. Nitto Denko

18.1.7.1. Overview

18.1.7.2. Product Portfolio

18.1.7.3. Profitability by Market Segments

18.1.7.4. Sales Footprint

18.1.7.5. Strategy Overview

18.1.7.5.1. Marketing Strategy

18.1.7.5.2. Product Strategy

18.1.7.5.3. Channel Strategy

18.1.8. RiboBio Co.

18.1.8.1. Overview

18.1.8.2. Product Portfolio

18.1.8.3. Profitability by Market Segments

18.1.8.4. Sales Footprint

18.1.8.5. Strategy Overview

18.1.8.5.1. Marketing Strategy

18.1.8.5.2. Product Strategy

18.1.8.5.3. Channel Strategy

18.1.9. LGC Biosearch Technologies

18.1.9.1. Overview

18.1.9.2. Product Portfolio

18.1.9.3. Profitability by Market Segments

18.1.9.4. Sales Footprint

18.1.9.5. Strategy Overview

18.1.9.5.1. Marketing Strategy

18.1.9.5.2. Product Strategy

18.1.9.5.3. Channel Strategy

18.1.10. Merck KGaA

18.1.10.1. Overview

18.1.10.2. Product Portfolio

18.1.10.3. Profitability by Market Segments

18.1.10.4. Sales Footprint

18.1.10.5. Strategy Overview

18.1.10.5.1. Marketing Strategy

18.1.10.5.2. Product Strategy

18.1.10.5.3. Channel Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Oligonucleotide API Market

Oligonucleotide API Market Forecast by Antisense Oligonucleotides APIs and Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs for 2024 to 2034